Manzo Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNZO research report →
About the company
Manzo Pharmaceuticals, Inc. is a specialized drug company that focuses on the discovery, creation, and evaluation of both proprietary and generic medical treatments and therapies. The company is actively developing Lacto-Freedom, a patented probiotic designed to help individuals with lactose intolerance digest dairy-containing foods more easily.
- CEO
- Kenneth Manzo
- IPO
- 1998
- Employees
- 12
- HQ
- Milford, PA, US
Price Chart
- Market Cap
- $115.95K
- P/E
- -9.83
- P/S
- 0.00
- P/B
- 2.76
- EV/EBITDA
- -1.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -763.99%
- ROIC
- -27.11%
- Revenue
- $0 · 0.00%
- Net Income
- $-50,851 · 0.00%
- EPS
- $0.00 · 0.00%
- Op Income
- $-52,154
- FCF YoY
- 0.00%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -44.70
- Avg Volume
- 43.08K
Get TickerSpark's AI analysis on MNZO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MNZO coverage
Recent articles, reports, and earnings notes.
No research on MNZO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MNZO report →Similar companies
Peers in the same neighborhood.